Related Experiment Video

Updated: Apr 27, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.7K

[Treatment of heart failure in diabetic patients]

Jaromír Hradec

    Vnitrni Lekarstvi
    |July 3, 2014
    PubMed

    Insights

    Diabetic patients with heart failure require standard treatments. However, some diabetes medications, like saxagliptin, may increase heart failure risk, necessitating careful cardiovascular safety evaluations for new drugs.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Diabetes mellitus and heart failure frequently coexist.
    • Standard heart failure treatments are generally applicable to diabetic patients.
    • Cardiovascular safety of anti-diabetic medications is a critical concern.

    Purpose of the Study:

    • To review the cardiovascular safety of anti-diabetic drugs, particularly in patients with heart failure.
    • To highlight recent findings on the increased incidence of heart failure associated with specific anti-diabetic agents.

    Main Methods:

    • Review of current treatment guidelines for heart failure in diabetic patients.
    • Analysis of clinical trial data and post-marketing surveillance regarding anti-diabetic drug safety.
    • Discussion of the cardiovascular effects of older and newer anti-diabetic agents.

    Main Results:

    • Older anti-diabetic drugs (insulin, metformin, sulfonylurea) are considered cardiovascularly safe.
    • Rosiglitazone (thiazolidinedione) was associated with increased cardiovascular events.
    • Saxagliptin, an incretin system affecting drug, has been linked to a higher incidence of heart failure.

    Conclusions:

    • While standard heart failure therapies are effective, careful selection of anti-diabetic medications is crucial.
    • Newer anti-diabetic agents require rigorous cardiovascular safety assessment due to potential risks like increased heart failure incidence.

    More Related Videos

    Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

    Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

    Published on: April 18, 2025

    749
    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.2K

    Related Concept Videos

    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    621
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    631
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    1.5K
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    1.7K
    Heart Failure VII: Nursing Interventions01:30

    Heart Failure VII: Nursing Interventions

    The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
    783
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
    2.6K